PARP inhibitors are a group of targeted medicines used in certain cases of ovarian cancer care. They work by interfering with cellular repair processes that cancer cells may depend on for survival. Their role can vary based on factors such as the type and stage of ovarian cancer, previous treatments, genetic characteristics, and overall health. Testing for changes in genes such as BRCA may help healthcare teams understand whether a PARP inhibitor could be relevant. Learning about how these medicines work, possible side effects, monitoring needs, and treatment decisions can help patients better understand this area of ovarian cancer care.
Ovarian cancer treatment may involve surgery, chemotherapy, targeted therapies, or a combination of approaches. PARP inhibitors are targeted medicines that have become an important part of treatment planning for some people with ovarian cancer. Their use depends on individual clinical factors and the characteristics of the cancer.
PARP stands for poly ADP ribose polymerase, which refers to a family of proteins involved in helping cells repair certain types of DNA damage. Cancer cells with specific genetic changes may rely more heavily on these repair mechanisms. By blocking PARP activity, these medicines can make it more difficult for some cancer cells to repair damage and continue growing.
Cells are exposed to DNA damage through normal biological processes. Healthy cells and cancer cells both have systems that help identify and repair this damage. Some ovarian cancers have changes in genes involved in DNA repair, including BRCA1 and BRCA2. These changes can affect how cancer cells respond when PARP activity is blocked.
PARP inhibitors may be considered as part of treatment or maintenance strategies in appropriate clinical situations. Their role can differ depending on whether the cancer has responded to earlier treatment and whether certain genetic or tumor-related characteristics are present.
The use of PARP inhibitors is not determined by one factor alone. A healthcare team may consider the type of ovarian cancer, treatment history, response to chemotherapy, genetic testing results, possible benefits, and potential risks before recommending a treatment approach.
Like other cancer treatments, PARP inhibitors can cause side effects, although experiences vary between individuals and medicines. Healthcare professionals may monitor patients through regular appointments, blood tests, and discussions about new or changing symptoms.
Some commonly discussed effects may include fatigue, nausea, changes in appetite, anemia, or changes in blood cell counts. Certain side effects may require closer medical monitoring or adjustments to treatment. Rare but serious complications can also occur, which is why regular follow-up is an important part of care.
Genetic counseling and testing can also play an important role in ovarian cancer care. Information about inherited or tumor-specific genetic changes may help guide treatment planning and may have implications for family members in some situations.
PARP inhibitors represent one area of targeted treatment in ovarian cancer care. Understanding how they affect DNA repair, why genetic testing may be relevant, and how treatment is monitored can help patients and families have informed discussions with qualified healthcare professionals. Individual treatment decisions should always be based on a complete medical evaluation and guidance from the treating oncology team.